DTIL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DTIL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Precision BioSciences's change in receivables for the quarter that ended in Mar. 2024 was $-0.85 Mil. It means Precision BioSciences's Accounts Receivable increased by $0.85 Mil from Dec. 2023 to Mar. 2024 .
Precision BioSciences's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.18 Mil. It means Precision BioSciences's Accounts Receivable increased by $0.18 Mil from Dec. 2022 to Dec. 2023 .
Precision BioSciences's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.39 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Precision BioSciences's Days Sales Outstanding for the three months ended in Mar. 2024 was 2.02.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Precision BioSciences's liquidation value for the three months ended in Mar. 2024 was $-9.48 Mil.
The historical data trend for Precision BioSciences's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precision BioSciences Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Change In Receivables | Get a 7-Day Free Trial | -0.44 | -9.04 | 9.51 | -0.23 | -0.18 |
Precision BioSciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | 0.03 | 0.04 | -2.84 | 2.59 | -0.85 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precision BioSciences (NAS:DTIL) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Precision BioSciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0.39 | / | 17.584 | * | 91 |
= | 2.02 |
2. In Ben Graham's calculation of liquidation value, Precision BioSciences's accounts receivable are only considered to be worth 75% of book value:
Precision BioSciences's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 137.766 | - | 147.535 | + | 0.75 * 0.39 | + | 0.5 * 0 |
= | -9.48 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Precision BioSciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
J. Jefferson Smith | 10 percent owner | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701 |
Alan List | officer: Chief Medical Officer | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701 |
Michael Amoroso | director, officer: President and CEO | 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Dario Scimeca | officer: General Counsel | C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701 |
John Alexander Kelly | officer: Interim CFO | C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
Pharma Ag Novartis | 10 percent owner | LICHTSTRASSE 35, CH-4002, BASEL V8 |
Ag Novartis | 10 percent owner | LICHTSTRASSE 35, BASEL V8 CH 4056 |
Derek Jantz | director, 10 percent owner, officer: Chief Scientific Officer | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701 |
Melinda Brown | director | 10 HUDSON YARDS, NEW YORK NY 10001 |
Shari Lisa Pire | director | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701 |
Samuel C. Wadsworth | director | C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
David S. Thomson | officer: Chief Development Officer | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701 |
Stanley Frankel | director | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701 |
Matthew R. Kane | director, 10 percent owner, officer: President and CEO | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701 |
Shane Barton | officer: VP & Corporate Controller | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701 |
From GuruFocus
By Business Wire • 07-27-2023
By Business Wire • 08-04-2023
By Business Wire • 11-07-2023
By Business Wire Business Wire • 05-09-2023
By Business Wire Business Wire • 05-02-2023
By Business Wire • 12-13-2023
By GuruFocus Research • 11-07-2023
By Business Wire • 10-23-2023
By Business Wire • 08-31-2023
By Business Wire • 09-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.